miR‑149‑5p inhibition reduces Alzheimer's disease &beta;‑amyloid generation in 293/APPsw cells by upregulating H4K16ac via KAT8

Chen,Fuyan; Chen,Huifeng; Jia,Yujie; Lu,Hai; Tan,Qiaorui; Zhou,Xin

doi:10.3892/etm.2020.9216

miR‑149‑5p inhibition reduces Alzheimer's disease β‑amyloid generation in 293/APPsw cells by upregulating H4K16ac via KAT8

Authors:
- Fuyan Chen
- Huifeng Chen
- Yujie Jia
- Hai Lu
- Qiaorui Tan
- Xin Zhou
View Affiliations

Affiliations: Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China, Department of Internal Neurology, Tianjin Medical University General Hospital Airport Hospital, Tianjin 300308, P.R. China, Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China, Department of Orthopedics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China
Published online on: September 11, 2020 https://doi.org/10.3892/etm.2020.9216
Article Number: 88
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease (AD), the leading cause of age‑related dementia, is characterized by abnormal β‑amyloid accumulation. During learning, memory formation and consolidation, increased levels of histone H3 and H4 acetylation are observed. The present study reported significantly decreased level of H4K16ac in the plasma of patients with AD compared with healthy subjects via western blotting and reverse transcription‑quantitative (RT‑q)PCR. Lysine acetyltransferase 8 (KAT8) expression, the major lysine acetyltransferase responsible for the acetylation of H4K16, was significantly decreased in patients with AD compared with healthy subjects as determined via western blotting and RT‑qPCR. The results indicated that aberrant expression patterns of H4K16ac and KAT8 might be associated with AD progression. Moreover, western blot analysis demonstrated that KAT8‑overexpression cells displayed increased levels of H4K16ac, accompanied by higher levels of neuroprotective soluble amyloid precursor protein (sAPP)α and β‑secretase (BACE)2, and decreased levels of sAPPβ and BACE1 compared with negative control and vector cells. In neurodegenerative disorders, microRNAs (miRNAs/miRs) are deregulated; however, the effect of miRNA dysregulation on histone acetylation is not completely understood. To the best of our knowledge, the present study identified a novel inhibitory interaction between miR‑149‑5p and KAT8 3'‑UTR that contributed to the pathological alterations in an AD cell model for the first time, using bioinformatics and a dual‑luciferase reporter assay. The western blotting results indicated that, compared with the inhibitor control group, miR‑149‑5p inhibitor markedly increased H4K16ac levels, which were significantly suppressed by co‑transfection with KAT8 short hairpin (sh)RNA. KAT8 shRNA and miR‑149‑5p inhibitor co‑transfection abolished the beneficial effects of miR‑149‑5p inhibitor. The results indicated that miR‑149‑5p regulated KAT8 and H4K16ac expression in an AD cell model, which may be associated with the pathological process of AD; therefore, miRNA may serve as a potential drug target for AD.

View Figures

View References

1	Nelson PT, Braak H and Markesbery WR: Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol. 68:1–14. 2009.PubMed/NCBI View Article : Google Scholar
2	Gouras GK, Olsson TT and Hansson O: β-Amyloid peptides and amyloid plaques in Alzheimer's disease. Neurotherapeutics. 12:3–11. 2015.PubMed/NCBI View Article : Google Scholar
3	Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, et al: Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 14:419–427. 1999.PubMed/NCBI View Article : Google Scholar
4	Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, et al: Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 402:533–537. 1999.PubMed/NCBI View Article : Google Scholar
5	Ourdev D, Foroutanpay BV, Wang Y and Kar S: The effect of Aβ1-42 oligomers on APP processing and Aβ1-40 generation in cultured U-373 astrocytes. Neurodegener Dis. 15:361–368. 2015.PubMed/NCBI View Article : Google Scholar
6	Zhang YW, Thompson R, Zhang H and Xu H: APP processing in Alzheimer's disease. Mol Brain. 4(3)2011.PubMed/NCBI View Article : Google Scholar
7	Kapsimali M, Kloosterman WP, de Bruijn E, Rosa F, Plasterk RH and Wilson SW: MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol. 8(R173)2007.PubMed/NCBI View Article : Google Scholar
8	Konopka W, Kiryk A, Novak M, Herwerth M, Parkitna JR, Wawrzyniak M, Kowarsch A, Michaluk P, Dzwonek J, Arnsperger T, et al: MicroRNA loss enhances learning and memory in mice. J Neurosci. 30:14835–14842. 2010.PubMed/NCBI View Article : Google Scholar
9	Li J and Wang H: miR-15b reduces amyloid-β accumulation in SH-SY5Y cell line through targetting NF-κB signaling and BACE1. Biosci Rep. 38(BSR20180051)2018.PubMed/NCBI View Article : Google Scholar
10	Santa-Maria I, Alaniz ME, Renwick N, Cela C, Fulga TA, Van Vactor D, Tuschl T, Clark LN, Shelanski ML, McCabe BD and Crary JF: Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest. 125:681–686. 2015.PubMed/NCBI View Article : Google Scholar
11	Ruan D, Liu Y, Wang X, Yang D and Sun Y: miR-149-5p protects against high glucose-induced pancreatic beta cell apoptosis via targeting the BH3-only protein BIM. Exp Mol Pathol. 110(104279)2019.PubMed/NCBI View Article : Google Scholar
12	Xiang F, Fan Y, Ni Z, Liu Q, Zhu Z, Chen Z, Hao W, Yue H, Wu R and Kang X: Ursolic acid reverses the chemoresistance of breast cancer cells to paclitaxel by targeting miRNA-149-5p/MyD88. Front Oncol. 9(501)2019.PubMed/NCBI View Article : Google Scholar
13	Lu H, Liu X, Deng Y and Qing H: DNA methylation, a hand behind neurodegenerative diseases. Front Aging Neurosci. 5(85)2013.PubMed/NCBI View Article : Google Scholar
14	Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD and Rogers J: Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging. 32:1161–1180. 2011.PubMed/NCBI View Article : Google Scholar
15	Aubry S, Shin W, Crary JF, Lefort R, Qureshi YH, Lefebvre C, Califano A and Shelanski ML: Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression. PLoS One. 10(e0120352)2015.PubMed/NCBI View Article : Google Scholar
16	Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al: Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 67:953–966. 2010.PubMed/NCBI View Article : Google Scholar
17	Lu X, Deng Y, Yu D, Cao H, Wang L, Liu L, Yu C, Zhang Y, Guo X and Yu G: Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer's disease. PLoS One. 9(e103067)2014.PubMed/NCBI View Article : Google Scholar
18	Marques SC, Lemos R, Ferreiro E, Martins M, de Mendonça A, Santana I, Outeiro TF and Pereira CM: Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience. 220:256–266. 2012.PubMed/NCBI View Article : Google Scholar
19	Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, Cota P, Wittnam JL, Gogol-Doering A, Opitz L, et al: Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 328:753–756. 2010.PubMed/NCBI View Article : Google Scholar
20	Walker MP, LaFerla FM, Oddo SS and Brewer GJ: Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. Age (Dordr). 35:519–531. 2013.PubMed/NCBI View Article : Google Scholar
21	Lau P, Frigerio CS and De Strooper B: Variance in the identification of microRNAs deregulated in Alzheimer's disease and possible role of lincRNAs in the pathology: The need of larger datasets. Ageing Res Rev. 17:43–53. 2014.PubMed/NCBI View Article : Google Scholar
22	Goldberg AD, Allis CD and Bernstein E: Epigenetics: A landscape takes shape. Cell. 128:635–638. 2007.PubMed/NCBI View Article : Google Scholar
23	Kouzarides T: Chromatin modifications and their function. Cell. 128:693–705. 2007.PubMed/NCBI View Article : Google Scholar
24	Yamakawa H, Cheng J, Penney J, Gao F, Rueda R, Wang J, Yamakawa S, Kritskiy O, Gjoneska E and Tsai LH: The transcription factor Sp3 cooperates with HDAC2 to regulate synaptic function and plasticity in neurons. Cell Rep. 20:1319–1334. 2017.PubMed/NCBI View Article : Google Scholar
25	Chuang DM, Leng Y, Marinova Z, Kim HJ and Chiu CT: Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32:591–601. 2009.PubMed/NCBI View Article : Google Scholar
26	Gräff J and Mansuy IM: Epigenetic dysregulation in cognitive disorders. Eur J Neurosci. 30:1–8. 2009.PubMed/NCBI View Article : Google Scholar
27	Sharma GG, So S, Gupta A, Kumar R, Cayrou C, Avvakumov N, Bhadra U, Pandita RK, Porteus MH, Chen DJ, et al: MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol. 30:3582–3595. 2010.PubMed/NCBI View Article : Google Scholar
28	Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM, et al: GWAS on family history of Alzheimer's disease. Transl Psychiatry. 8(99)2018.PubMed/NCBI View Article : Google Scholar
29	Chatterjee A, Seyfferth J, Lucci J, Gilsbach R, Preissl S, Böttinger L, Mårtensson CU, Panhale A, Stehle T, Kretz O, et al: MOF acetyl transferase regulates transcription and respiration in mitochondria. Cell. 167:722–738 e723. 2016.PubMed/NCBI View Article : Google Scholar
30	Guo R, Fan G, Zhang J, Wu C, Du Y, Ye H, Li Z, Wang L, Zhang Z, Zhang L, et al: A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer's disease. J Alzheimers Dis. 60:1365–1377. 2017.PubMed/NCBI View Article : Google Scholar
31	Tamaoka A: Alzheimer's disease: Definition and national institute of neurological and communicative disorders and stroke and the Alzheimer's disease and related disorders association (NINCDS-ADRDA). Nihon Rinsho. 2 (Suppl 69):S240–S245. 2011.PubMed/NCBI(In Japanese).
32	Haris M, Singh A, Cai K, McArdle E, Fenty M, Davatzikos C, Trojanowski JQ, Melhem ER, Clark CM and Borthakur A: T(1p) MRI in Alzheimer's disease: Detection of pathological changes in medial temporal lobe. J Neuroimaging. 21:e86–e90. 2011.
33	Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK and Bromet E: Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. 35:1022–1029. 2009.PubMed/NCBI View Article : Google Scholar
34	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
35	Mews P, Donahue G, Drake AM, Luczak V, Abel T and Berger SL: Acetyl-CoA synthetase regulates histone acetylation and hippocampal memory. Nature. 546:381–386. 2017.PubMed/NCBI View Article : Google Scholar
36	Gräff J and Tsai LH: The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol. 53:311–330. 2013.PubMed/NCBI View Article : Google Scholar
37	Levenson JM, O'Riordan KJ, Brown KD, Trinh MA, Molfese DL and Sweatt JD: Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem. 279:40545–40559. 2004.PubMed/NCBI View Article : Google Scholar
38	Basi G, Frigon N, Barbour R, Doan T, Gordon G, McConlogue L, Sinha S and Zeller M: Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. J Biol Chem. 278:31512–31520. 2003.PubMed/NCBI View Article : Google Scholar
39	Sun X, He G and Song W: BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in down syndrome. FASEB J. 20:1369–1376. 2006.PubMed/NCBI View Article : Google Scholar
40	Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018.PubMed/NCBI View Article : Google Scholar
41	Zetterberg H and Burnham SC: Blood-based molecular biomarkers for Alzheimer's disease. Mol Brain. 12(26)2019.PubMed/NCBI View Article : Google Scholar
42	Gräff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJF, Fass DM, Kao PF, Kahn M, et al: An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 483:222–226. 2012.PubMed/NCBI View Article : Google Scholar
43	Dorszewska J, Prendecki M, Oczkowska A, Dezor M and Kozubski W: Molecular basis of familial and sporadic Alzheimer's disease. Curr Alzheimer Res. 13:952–963. 2016.PubMed/NCBI View Article : Google Scholar
44	Wang L, Liu J, Wang Q, Jiang H, Zeng L, Li Z and Liu R: MicroRNA-200a-3p mediates neuroprotection in Alzheimer-related deficits and attenuates amyloid-beta overproduction and tau hyperphosphorylation via coregulating BACE1 and PRKACB. Front Pharmacol. 10(806)2019.PubMed/NCBI View Article : Google Scholar
45	Long JM, Ray B and Lahiri DK: MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem. 289:5184–5198. 2014.PubMed/NCBI View Article : Google Scholar
46	Jia LH and Liu YN: Downregulated serum miR-223 servers as biomarker in Alzheimer's disease. Cell Biochem Funct. 34:233–237. 2016.PubMed/NCBI View Article : Google Scholar
47	Kumar S, Vijayan M and Reddy PH: MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease. Hum Mol Genet. 26:3808–3822. 2017.PubMed/NCBI View Article : Google Scholar
48	Zhang B, Chen CF, Wang AH and Lin QF: miR-16 regulates cell death in Alzheimer's disease by targeting amyloid precursor protein. Eur Rev Med Pharmacol Sci. 19:4020–4027. 2015.PubMed/NCBI
49	Chen W, Zhang J, Xu H, Dai J and Zhang X: The negative regulation of miR-149-5p in melanoma cell survival and apoptosis by targeting LRIG2. Am J Transl Res. 9:4331–4340. 2017.PubMed/NCBI
50	Xu RD, Feng F, Yu XS, Liu ZD and Lao LF: miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma. Int J Immunopathol Pharmacol. 32(2058738418786656)2018.PubMed/NCBI View Article : Google Scholar
51	Sundermann EE, Heaton RK, Pasipanodya E, Moore RC, Paolillo EW, Rubin LH, Ellis R, Moore DJ and Group HNRP: Sex differences in HIV-associated cognitive impairment. AIDS. 32:2719–2726. 2018.PubMed/NCBI View Article : Google Scholar
52	Norman MA, Moore DJ, Taylor M, Franklin D Jr, Cysique L, Ake C, Lazarretto D, Vaida F, Heaton RK and Group HNRC: Demographically corrected norms for African Americans and caucasians on the hopkins verbal learning test-revised, brief visuospatial memory test-revised, stroop color and word test, and wisconsin card sorting test 64-card version. J Clin Exp Neuropsychol. 33:793–804. 2011.PubMed/NCBI View Article : Google Scholar